Business
Immunic, Inc. Expands Board of Directors with Appointment of Industry Veteran Tamar Howson
SAN DIEGO, Oct. 15, 2019 /PRNewswire/ -- Immunic, Inc. (Nasdaq: IMUX), a clinical-stage biopharmaceutical company focused on developing best-in-class, oral
About this update from Immunic, Inc.
[{"type":"text","content":"SAN DIEGO, Oct. 15, 2019 /PRNewswire/ -- Immunic, Inc. (Nasdaq: IMUX), a clinical-stage biopharmaceutical company focused on developing best-in-class, oral therapies for the treatment of chronic inflammatory and autoimmune diseases, today announced the appointment of Tamar Howson, a highly seasoned life sciences executive, to its Board of Directors, effective October 11, 2019. With this addition, Immunic's Board now totals six members.\n\"Tamar brings to Immunic more than thirty years of relevant experience in corporate and business development, having worked in-house, and as a consultant and Board member for a wide range of companies in the biotechnology and pharmaceutical industries,\" stated Duane Nash, M.D., J.D., M.B.A., Chairman of the Board of Directors of Immunic. \"Her vast industry expertise and proven leadership capabilities make her a valuable asset, and we look forward to leveraging her knowledge and insights as we progress our clinical and preclinical pipeline activities.\"\nMs. Howson is currently an Independent Director at MEI Pharma, Inc. and Scientus Pharma Inc., and, until recently, was an Independent Director at Organovo Holdings, Inc. Earlier, she was a Senior Advisor on the transaction team at JSB-Partners, providing business development support to life sciences companies. Before that, she served as Executive Vice President, Corporate Business Development at Lexicon Pharmaceuticals, Inc. Prior, Ms. Howson was Senior Vice President, Corporate and Business Development at Bristol-Myers Squibb Company, responsible for worldwide oversight and management of the identification, evaluation and negotiation of mergers and acquisitions, licensing and other external alliance activities. Additionally, Ms. Howson spent nearly a decade at SmithKline Beecham, where she served as Senior Vice President and Director, Business Development and managed the company's USD 100 million venture capital fund, SR One.\nDuring her career, Ms. Howson has also served on the boards of companies including Actavis Pharma, Inc., ContraVir Pharmaceuticals, Inc., Cynapsus Therapeutics Inc., Enzymotec Ltd., Idenix Pharmaceuticals, Inc., IPM-International Partnership for Microbicides and OXiGENE, Inc. \nMs. Howson earned a Bachelor of Science in chemical engineering from the Technion - Israeli Institute of Technology, a Master of Science in chemi...